Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Oncol.

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): Jan 10 2016

Volume: 34

Issue: 2

Affiliations

[1 ] Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Jun Liu, Rashmi Kanagal-Shamanna, Jing Ning, Summer E. Hanson, Loretta J. Nastoupil, Yasuhiro Oki, Ken H. Young, and Roberto N. Miranda, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Horwitz, Neha Mehta-Shah, Ahmed Dogan, and Colleen M. McCarthy, Memorial Sloan Kettering Cancer Center, New York, NY; Dennis D. Weisenburger, City of Hope National Medical Center, Duarte, CA; Elizabeth A. Morgan, Brigham and Women's Hospital and Harvard Medical School; Aliyah R. Sohani and Judith A. Ferry, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Vinita Parkash, Yale School of Medicine, New Haven, CT; Hui Liu, Xuzhou Medical College, Xuzhou, People's Republic of China; Nora Thormann, Fundacao Universitaria Mario Martins, Porto Alegre, Brazil; Arianna DiNapoli, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Stephen Lade, University of Melbourne, Melbourne, Victoria, Australia; Jorge Piccolini, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Ruben Reyes, Kansas University Medical Center, Kansas City, KS; Travis Williams, St Luke's Mountain States Tumor Institute, Meridian, ID; and Rakesh Gaur, St Luke's Hospital, Kansas City, MO.

[2 ] Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Jun Liu, Rashmi Kanagal-Shamanna, Jing Ning, Summer E. Hanson, Loretta J. Nastoupil, Yasuhiro Oki, Ken H. Young, and Roberto N. Miranda, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Horwitz, Neha Mehta-Shah, Ahmed Dogan, and Colleen M. McCarthy, Memorial Sloan Kettering Cancer Center, New York, NY; Dennis D. Weisenburger, City of Hope National Medical Center, Duarte, CA; Elizabeth A. Morgan, Brigham and Women's Hospital and Harvard Medical School; Aliyah R. Sohani and Judith A. Ferry, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Vinita Parkash, Yale School of Medicine, New Haven, CT; Hui Liu, Xuzhou Medical College, Xuzhou, People's Republic of China; Nora Thormann, Fundacao Universitaria Mario Martins, Porto Alegre, Brazil; Arianna DiNapoli, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Stephen Lade, University of Melbourne, Melbourne, Victoria, Australia; Jorge Piccolini, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Ruben Reyes, Kansas University Medical Center, Kansas City, KS; Travis Williams, St Luke's Mountain States Tumor Institute, Meridian, ID; and Rakesh Gaur, St Luke's Hospital, Kansas City, MO. roberto.miranda@mdanderson.org.

Article

Publisher Item ID: JCO.2015.63.3412

DOI: 10.1200/JCO.2015.63.3412

PMC ID: 4872006

PubMed ID: 26628470

SO-VID: 697d216c-d929-41ec-917a-b4b29ebf0ccc

History

Data availability:

Comments

Comment on this article

scite_

Cited by 135

See all cited by